[
  {
    "ts": null,
    "headline": "NHS must pay ‘fair share’, says US drug giant amid Trump pressure",
    "summary": "The NHS must pay more towards new drug development to help cut prices for Americans, a major US pharmaceutical giant has said.",
    "url": "https://finnhub.io/api/news?id=4232d13b8b14cd5bdd3f2a31febe754ece494b58991311ac3baf9fa7c6c5c347",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758560827,
      "headline": "NHS must pay ‘fair share’, says US drug giant amid Trump pressure",
      "id": 136851178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The NHS must pay more towards new drug development to help cut prices for Americans, a major US pharmaceutical giant has said.",
      "url": "https://finnhub.io/api/news?id=4232d13b8b14cd5bdd3f2a31febe754ece494b58991311ac3baf9fa7c6c5c347"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Commits to Veeva Vault CRM",
    "summary": "Veeva Systems (NYSE: VEEV) today announced that Bristol Myers Squibb (BMS) has committed to Veeva Vault CRM.",
    "url": "https://finnhub.io/api/news?id=de84ecca275af40064f5101f0bc99f9eefc51a30706257191cd33a3319af1a25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758549780,
      "headline": "Bristol Myers Squibb Commits to Veeva Vault CRM",
      "id": 136851179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Veeva Systems (NYSE: VEEV) today announced that Bristol Myers Squibb (BMS) has committed to Veeva Vault CRM.",
      "url": "https://finnhub.io/api/news?id=de84ecca275af40064f5101f0bc99f9eefc51a30706257191cd33a3319af1a25"
    }
  },
  {
    "ts": null,
    "headline": "MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug",
    "summary": "The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.",
    "url": "https://finnhub.io/api/news?id=cbe20e0bdf8b8713e3108720caabcdc66b4ba11c6e736c00b0692884205fe900",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758542460,
      "headline": "MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug",
      "id": 136851180,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.",
      "url": "https://finnhub.io/api/news?id=cbe20e0bdf8b8713e3108720caabcdc66b4ba11c6e736c00b0692884205fe900"
    }
  }
]